Enovis Corporation (ENOV)
| Market Cap | 1.05B -38.5% |
| Revenue (ttm) | 2.30B +4.9% |
| Net Income | -1.10B |
| EPS | -19.22 |
| Shares Out | 57.67M |
| PE Ratio | n/a |
| Forward PE | 5.04 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,942,981 |
| Open | 18.51 |
| Previous Close | 18.46 |
| Day's Range | 18.08 - 18.70 |
| 52-Week Range | 17.30 - 34.28 |
| Beta | 1.48 |
| Analysts | Strong Buy |
| Price Target | 38.33 (+109.8%) |
| Est. Earnings | Nov 5, 2026 |
About ENOV
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary ca... [Read more]
Financial Performance
In 2025, Enovis's revenue was $2.25 billion, an increase of 6.66% compared to the previous year's $2.11 billion. Losses were -$1.18 billion, 43.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for ENOV stock is "Strong Buy." The 12-month stock price target is $38.33, which is an increase of 109.80% from the latest price.
News
Enovis becomes first multi-registry industry sponsor of AAOS Registry Program
Company expands its support from the American Joint Replacement Registry to include the Shoulder & Elbow Registry ROSEMONT, Ill., Sept. 22, 2026 /PRNewswire/ -- The American Academy of Orthopaedic Sur...
Enovis management to meet virtually with Freedom Capital
Virtual Meeting to be held on September 22 hosted by Freedom Capital.
Enovis Transcript: Wells Fargo 21st Annual Healthcare Conference
Ortho market growth remains robust, with share gains in Europe and strong U.S. performance. The eCential acquisition accelerates robotics strategy, with a U.S. knee launch in 2028 and integrated AI-powered systems. Financial targets include 50% free cash flow conversion next year and margin expansion resuming in 2028.
Enovis price target lowered to $36 from $40 at BTIG
BTIG lowered the firm’s price target on Enovis (ENOV) to $36 from $40 and keeps a Buy rating on the shares. The firm is updating its model for incremental costs…
Enovis price target lowered to $47 from $55 at Citizens
Citizens lowered the firm’s price target on Enovis (ENOV) to $47 from $55 and keeps an Outperform rating on the shares after the company announced the acquisition of eCential Robotics.
Enovis price target lowered to $36 from $40 at BTIG
BTIG lowered the firm’s price target on Enovis (ENOV) to $36 from $40 and keeps a Buy rating on the shares after the company announced a binding offer to acquire…
Enovis price target lowered to $27 from $30 at BMO Capital
BMO Capital lowered the firm’s price target on Enovis (ENOV) to $27 from $30 and keeps an Outperform rating on the shares after the company acquired eCential Robotics for EUR…
Enovis Transcript: M&A announcement
The acquisition of eCential Robotics accelerates the company’s entry into surgical robotics, focusing on knee and shoulder applications with a unified technology platform. The €155M deal, plus milestones, is expected to drive long-term growth, innovation, and margin improvement by 2029.
Enovis Slides: M&A announcement
Enovis has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
Enovis Press release: M&A announcement
Enovis issued a press release on September 1, 2026, disclosing material business information to investors.
eCential Robotics Announces Binding Offer from Enovis
eCential Robotics platform to join Enovis' enabling technology portfolio. GRENOBLE, France and FRANKLIN, Tenn.
Enovis enters binding offer to acquire eCential Robotics for EUR 155M upfront
Enovis (ENOV) announced that it has entered into a binding offer to acquire eCential Robotics. The acquisition expands the ASTRA enabling technology platform with robotic automation capabilities. Unde...
Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical Robotics
Dallas, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- – Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced today that it has entered into a binding offer to acquire ...
Enovis to Participate in the 2026 Wells Fargo Healthcare Conference
Dallas, TX, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will participate in the 2026 Wells Farg...
Enovis price target lowered to $45 from $50 at Canaccord
Canaccord lowered the firm’s price target on Enovis (ENOV) to $45 from $50 and keeps a Buy rating on the shares. The firm updated its mode following Q2 results. Published…
Enovis price target raised to $30 from $29 at BMO Capital
BMO Capital analyst Vik Chopra raised the firm’s price target on Enovis (ENOV) to $30 from $29 and keeps an Outperform rating on the shares.
Enovis Earnings Call Transcript: Q2 2026
Q2 2026 delivered 5% organic growth, margin expansion, and strong free cash flow, driven by new product launches and commercial execution. Guidance for 2026 is reaffirmed, with expectations for sales acceleration in Q4 and continued focus on margin and cash flow improvement.
Enovis Earnings release: Q2 2026
Enovis released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Enovis Slides: Q2 2026
Enovis has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Enovis Quarterly report: Q2 2026
Enovis has published its Q2 2026 quarterly earnings report on August 6, 2026.
Enovis reports Q2 adjusted EPS 90c, consensus 85c
Reports Q2 revenue $583M, consensus $581.84M. “Our second-quarter results reflect a more focused organization and a portfolio that has been meaningfully reshaped over the past several years,” said Dam...
Enovis backs FY26 adjusted EPS view $3.52-$3.73, consensus $3.64
Enovis (ENOV) reaffirmed financial expectations for 2026. Revenue is expected to be in a range of $2.31B-2.37B, which incorporates 4%-6% organic revenue growth. FY26 consensus $2.34B. Adjusted EBITDA ...
Enovis Announces Second Quarter 2026 Results
Second-quarter sales growth of 3% on a reported basis, 5% organic Second-quarter Reconstructive sales grew 8% on a reported basis, 6% organic Reaffirmed full-year 2026 guidance for revenue, adjusted E...
Enovis assumed with a Buy at UBS
UBS assumed coverage of Enovis (ENOV) with a Buy rating with a price target of $51, up from $50. Concerns over Enovis’s Lima integration and free cash flow are easing,…
Enovis to Host Second Quarter 2026 Results Conference Call on August 6th
Dallas, TX, July 17, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and liv...